Evidence map›Paper›PMID 26112821›Full record

ArticlePharmacoepidemiology and drug safety2016

Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines.

Gema Requena, John Logie, Elisa Martin, Nada Boudiaf, Rocío González González, Consuelo Huerta, Arturo Alvarez, David Webb, Andrew Bate, Luis A García Rodríguez and 7 more

Abstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Gema RequenaPharmacology Unit, Department of Biomedical Sciences, School of Medicine, University of Alcalá, Madrid, Spain.
John LogieWorldwide Epidemiology, GlaxoSmithKline, Research and Development, Uxbridge, Middlesex, UK.
Elisa MartinBIFAP Research Unit, Spanish Agency of Medicines and Medical Devices, Madrid, Spain.
Nada BoudiafWorldwide Epidemiology, GlaxoSmithKline, Research and Development, Uxbridge, Middlesex, UK.
Rocío González GonzálezBIFAP Research Unit, Spanish Agency of Medicines and Medical Devices, Madrid, Spain.
Consuelo HuertaBIFAP Research Unit, Spanish Agency of Medicines and Medical Devices, Madrid, Spain.
Arturo AlvarezBIFAP Research Unit, Spanish Agency of Medicines and Medical Devices, Madrid, Spain.
David WebbWorldwide Epidemiology, GlaxoSmithKline, Research and Development, Uxbridge, Middlesex, UK.
Andrew BateEpidemiology, Pfizer Ltd, Tadworth, UK.
Luis A García RodríguezSpanish Center for Pharmacoepidemiological Research (CEIFE), Madrid, Spain.
Robert ReynoldsEpidemiology, Pfizer Research and Development, New York, USA.
Raymond SchliengerGlobal Clinical Epidemiology, Novartis Pharma AG, Basel, Switzerland.
Helga GardarsdottirDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands.
Mark de GrootDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0002-5764-5788
Olaf H KlungelDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands.
Fancisco de AbajoPharmacology Unit, Department of Biomedical Sciences, School of Medicine, University of Alcalá, Madrid, Spain.
Ian J DouglasLondon School of Hygiene and Tropical Medicine (LSHTM), London, UK.

Funding

Medical Research Council G0802403
6 · The paper itself

Abstract

backgroundThe case-crossover (CXO) and self-controlled case series (SCCS) designs are increasingly used in pharmacoepidemiology. In both, relative risk estimates are obtained within persons, implicitly controlling for time-fixed confounding variables.

objectivesTo examine the consistency of relative risk estimates of hip/femur fractures (HFF) associated with the use of benzodiazepines (BZD) across case-only designs in two databases (DBs), when a common protocol was applied.

methodsCXO and SCCS studies were conducted in BIFAP (Spain) and CPRD (UK). Exposure to BZD was divided into non-use, current, recent and past use. For CXO, odds ratios (OR; 95%CI) of current use versus non-use/past were estimated using conditional logistic regression adjusted for co-medications (AOR). For the SCCS, conditional Poisson regression was used to estimate incidence rate ratios (IRR; 95%CI) of current use versus non/past-use, adjusted for age. To investigate possible event-exposure dependence the relative risk in the 30 days prior to first BZD exposure was also evaluated.

resultsIn the CXO current use of BZD was associated with an increased risk of HFF in both DBs, AORBIFAP = 1.47 (1.29-1.67) and AORCPRD = 1.55 (1.41-1.70). In the SCCS, IRRs for current exposure was 0.79 (0.72-0.86) in BIFAP and 1.21 (1.13-1.30) in CPRD. However, when we considered separately the 30-day pre-exposure period, the IRR for current period was 1.43 (1.31-1.57) in BIFAP and 1.37 (1.27-1.47) in CPRD.

conclusionsCXO designs yielded consistent results across DBs, while initial SCCS analyses did not. Accounting for event-exposure dependence, estimates derived from SCCS were more consistent across DBs and designs.

Indexed as

BenzodiazepinesCase-Control StudiesDatabases, FactualFemaleHip FracturesHumansMaleResearch DesignBenzodiazepinesbenzodiazepinescase crossover (CXO)electronic healthcare records databases (DBs)hip fracturespharmacoepidemiologyself-controlled case series (SCCS)

Identifiers

PMID26112821
PMCPMC4949640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.